Evidence map›Paper›PMID 33292786›Full record

ArticleClinical diabetes and endocrinology2020

Acromegaly and thyroid cancer: analysis of evolution in a series of patients.

Karina Danilowicz, Soledad Sosa, Mariana Soledad Gonzalez Pernas, Elizabeth Bamberger, Sabrina Mara Diez, Patricia Fainstein-Day, Alejandra Furioso, Mariela Glerean, Mirtha Guitelman, Débora Katz and 14 more

Open access · goldAbstract read
In one paragraph

Article in Clinical diabetes and endocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 10 institutions in 1 country.

Karina DanilowiczEndocrinology Division, Hospital de Clínicas José de San Martín- Universidad de Buenos Aires, Buenos Aires, Argentina. kdanilowicz@hotmail.com.ORCID http://orcid.org/0000-0003-3153-3793
Soledad SosaEndocrinology Division, Hospital de Clínicas José de San Martín- Universidad de Buenos Aires, Buenos Aires, Argentina.
Mariana Soledad Gonzalez PernasNeuroendocrine Department, Sociedad Argentina de Endocrinología y Metabolismo, Buenos Aires, Argentina.
Elizabeth BambergerNeuroendocrine Department, Sociedad Argentina de Endocrinología y Metabolismo, Buenos Aires, Argentina.
Sabrina Mara DiezNeuroendocrine Department, Sociedad Argentina de Endocrinología y Metabolismo, Buenos Aires, Argentina.
Patricia Fainstein-DayNeuroendocrine Department, Sociedad Argentina de Endocrinología y Metabolismo, Buenos Aires, Argentina.
Alejandra FuriosoNeuroendocrine Department, Sociedad Argentina de Endocrinología y Metabolismo, Buenos Aires, Argentina.
Mariela GlereanNeuroendocrine Department, Sociedad Argentina de Endocrinología y Metabolismo, Buenos Aires, Argentina.
Mirtha GuitelmanNeuroendocrine Department, Sociedad Argentina de Endocrinología y Metabolismo, Buenos Aires, Argentina.
Débora KatzNeuroendocrine Department, Sociedad Argentina de Endocrinología y Metabolismo, Buenos Aires, Argentina.
Nicole LemaitreEndocrinology Division, Hospital Ángel C. Padilla, Tucumán, Argentina.
Alicia LowensteinEndocrinology Division, Hospital Ramos Mejía, Buenos Aires, Argentina.
Mariela Del Valle LunaEndocrinology Division, Hospital Ángel C. Padilla, Tucumán, Argentina.
María Paz MartínezEndocrinology Division, Hospital Alemán, Buenos Aires, Argentina.
Karina MiragayaNeuroendocrine Department, Sociedad Argentina de Endocrinología y Metabolismo, Buenos Aires, Argentina.
Daniel MoncetEndocrinology Division, Hospital Privado de Comunidad, Mar del Plata, Buenos Aires, Argentina.
María Victoria OrtuñoEndocrinology Division, Hospital Alemán, Buenos Aires, Argentina.
Analía PignattaEndocrinology Division, Hospital Interzonal San Juan Bautista, San Fernando del Valle de Catamarca, Catamarca, Argentina.
Constanza Fernanda RamacciottiEndocrinology Division, Hospital Privado Universitario de Córdoba, Córdoba, Argentina.
Adriana ReyesEndocrinology Division, Hospital Ramos Mejía, Buenos Aires, Argentina.
Amelia Susana RogozinskiNeuroendocrine Department, Sociedad Argentina de Endocrinología y Metabolismo, Buenos Aires, Argentina.
Patricia SlavinskyNeuroendocrine Department, Sociedad Argentina de Endocrinología y Metabolismo, Buenos Aires, Argentina.
Julieta TkatchNeuroendocrine Department, Sociedad Argentina de Endocrinología y Metabolismo, Buenos Aires, Argentina.
Fabián PitoiaEndocrinology Division, Hospital de Clínicas José de San Martín- Universidad de Buenos Aires, Buenos Aires, Argentina.
Hospital Ramos Mejía · ARFundación para la Lucha contra las Enfermedades Neurológicas de la Infancia · ARInstituto de Neurología Cognitiva · ARUniversidad de Buenos Aires · AREl Hospital General de Agudos Carlos G. Durand · ARHospital Alemán · ARHospital Italiano de Buenos Aires · ARHospital Privado · ARHospital Privado de Comunidad · ARNational University of Catamarca · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcromegaly is associated with higher morbidity and mortality mainly due to cardiovascular disease. Data on the incidence and evolution of thyroid cancer in acromegaly are controversial. Our objective was to describe the characteristics of a group of acromegalic patients with differentiated thyroid carcinoma (DTC) and analyze their evolution.

methodsThis is a retrospective multicenter study of 24 acromegalic patients with DTC. The AJCC Staging System 8th Edition was used for TNM staging, and the initial risk of recurrence (RR), initial response and response at the end of follow-up (RFU) were defined according to the 2015 ATA Guidelines. As a control group, 92 patients with DTC without acromegaly were randomly included. Statistical analyses were done using SPSS Statistics 20.0.

resultsMedian age of patients at diagnosis of acromegaly was 49.5 years (range 12-69). The median delay in diagnosis of acromegaly was 3 years (range 0.5-23). Mean baseline IGF-1 level was 2.9 ± 1.1 ULN. Median age at DTC diagnosis was 51.5 years (18-69). At the moment of diagnosis of DTC, 58.3% of the patients had active acromegaly. Median time from DTC diagnosis to acromegaly control was 1.25 years (0.5-7). Mean DTC tumor diameter of the biggest lesion was 14.6 ± 9.2 mm, being multifocal in 37.5%. All tumors were papillary carcinomas, two cases being of an aggressive variety. Lymph node dissection was performed in 8 out of 24 patients and 62.5% had metastases. Only one patient had distant metastases. Radioiodine ablation was given to 87.5% of patients. Nineteen patients (79%) were stage I, four (17%) stage II and one (4%) stage IVb. Initial RR was low in 87% (21/24), intermediate in 9% (2/24) and high in 4% (1/24) patient. RFU was: 83% (19/23) patients with no evidence of disease, 9% (2/23) with indeterminate response, 4% (1/23) with biochemical incomplete response and 4% (1/23) with structural incomplete response, at a median time of FU of 36.5 months. When comparing RFU between acromegalics and controls no statistically significant differences were found.

conclusionsPatients with acromegaly and DTC mostly had a low initial RR. When compared with the control group, we found that DTC patients with acromegaly did not have a worse evolution.

Indexed as

AcromegalyNeoplasmsThyroidThyroid cancerThyroid nodule

Identifiers

PMID33292786
PMCPMC7672811
OpenAlexW3099534174

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.